Literature DB >> 28858744

Initial validation of a proxy indicator of functioning as a potential tool for establishing a clinically meaningful cocaine use outcome.

Brian D Kiluk1, Theresa A Babuscio2, Charla Nich2, Kathleen M Carroll2.   

Abstract

BACKGROUND: Establishing a non-abstinence cocaine use outcome as clinically meaningful has been elusive, in part due to the lack of association between cocaine use outcomes and meaningful indicators of long-term functioning.
METHODS: Using data pooled across 7 clinical trials evaluating treatments for cocaine (N=718), a dichotomous indicator of functioning was created to represent a meaningful outcome ('problem-free functioning' - PFF), defined as the absence of problems across non-substance-related domains on the Addiction Severity Index. Its validity was evaluated at multiple time points (baseline, end-of-treatment, terminal follow-up) and used to explore associations with cocaine use.
RESULTS: The percentage of participants meeting PFF criteria increased over time (baseline=18%; end-of-treatment=32%; terminal follow-up=37%). At each time point, ANOVAs indicated those who met PFF criteria reported significantly less distress on the Brief Symptom Inventory and less perceived stress on the Perceived Stress Scale. Generalized linear models indicated categorical indices of self-reported cocaine use at the end of treatment were predictive of the probability of meeting PFF criteria during follow-up (β=-0.01, p<0.01; 95% CI: -0.008 to -0.003), with those reporting 0days or 1-4days ('occasional' use) in the final month of treatment showing an increased likelihood of achieving PFF.
CONCLUSIONS: Initial validation of a proxy indicator of problem-free functioning demonstrated criterion validity and sensitivity to change over time. Frequency of cocaine use in the final month of treatment was associated with PFF during follow-up, with strongest associations between PFF and abstinence or 'occasional' use.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Addiction severity index; Clinically meaningful outcome; Cocaine; Functioning

Mesh:

Substances:

Year:  2017        PMID: 28858744      PMCID: PMC5611843          DOI: 10.1016/j.drugalcdep.2017.07.020

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  33 in total

1.  On the practice of dichotomization of quantitative variables.

Authors:  Robert C MacCallum; Shaobo Zhang; Kristopher J Preacher; Derek D Rucker
Journal:  Psychol Methods       Date:  2002-03

Review 2.  Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.

Authors:  A T McLellan; D C Lewis; C P O'Brien; H D Kleber
Journal:  JAMA       Date:  2000-10-04       Impact factor: 56.272

3.  The inventory of drug use consequences (InDUC): test-retest stability and sensitivity to detect change.

Authors:  J Scott Tonigan; William R Miller
Journal:  Psychol Addict Behav       Date:  2002-06

4.  Studies of the reliability and validity of the Addiction Severity Index.

Authors:  Klaus Mäkelä
Journal:  Addiction       Date:  2004-04       Impact factor: 6.526

5.  The Addiction Severity Index at 25: origins, contributions and transitions.

Authors:  A Thomas McLellan; John C Cacciola; Arthur I Alterman; Samuel H Rikoon; Deni Carise
Journal:  Am J Addict       Date:  2006 Mar-Apr

6.  Generalizability of the clinical dimensions of the Addiction Severity Index to nonopioid-dependent patients.

Authors:  A I Alterman; P A McDermott; T G Cook; J S Cacciola; J R McKay; A T McLellan; M J Rutherford
Journal:  Psychol Addict Behav       Date:  2000-09

7.  Predictive validity of the Addiction Severity Index's composite scores in the assessment of 2-year outcomes in a methadone maintenance population.

Authors:  G B Bovasso; A I Alterman; J S Cacciola; T G Cook
Journal:  Psychol Addict Behav       Date:  2001-09

8.  The Addiction Severity Index medical and psychiatric composite scores measure similar domains as the SF-36 in substance-dependent veterans: concurrent and discriminant validity.

Authors:  Donald A Calsyn; Andrew J Saxon; Kristen R Bush; Donelle N Howell; John S Baer; Kevin L Sloan; Carol A Malte; Daniel R Kivlahan
Journal:  Drug Alcohol Depend       Date:  2004-11-11       Impact factor: 4.492

9.  The Fifth Edition of the Addiction Severity Index.

Authors:  A T McLellan; H Kushner; D Metzger; R Peters; I Smith; G Grissom; H Pettinati; M Argeriou
Journal:  J Subst Abuse Treat       Date:  1992

10.  Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial.

Authors:  Kathleen M Carroll; Lisa R Fenton; Samuel A Ball; Charla Nich; Tami L Frankforter; Julia Shi; Bruce J Rounsaville
Journal:  Arch Gen Psychiatry       Date:  2004-03
View more
  9 in total

1.  Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder.

Authors:  Dustin C Lee; Nicolas J Schlienz; Erica N Peters; Robert H Dworkin; Dennis C Turk; Eric C Strain; Ryan Vandrey
Journal:  Drug Alcohol Depend       Date:  2018-11-15       Impact factor: 4.492

2.  Short and long-term improvements in psychiatric symptomatology to validate clinically meaningful treatment outcomes for cocaine use disorders.

Authors:  André Q C Miguel; Brian D Kiluk; Theresa A Babuscio; Charla Nich; Jair J Mari; Kathleen M Carroll
Journal:  Drug Alcohol Depend       Date:  2019-03-20       Impact factor: 4.492

3.  Sociodemographic and clinical outcome differences among individuals seeking treatment for cocaine use disorders. The intersection of gender and race.

Authors:  André Q C Miguel; Ayana Jordan; Brian D Kiluk; Charla Nich; Theresa A Babuscio; Jair J Mari; Kathleen M Carroll
Journal:  J Subst Abuse Treat       Date:  2019-08-28

4.  Patterns of Cocaine Use During Treatment: Associations With Baseline Characteristics and Follow-Up Functioning.

Authors:  Corey R Roos; Charla Nich; Chung Jung Mun; Justin Mendonca; Theresa A Babuscio; Katie Witkiewitz; Kathleen M Carroll; Brian D Kiluk
Journal:  J Stud Alcohol Drugs       Date:  2019-07       Impact factor: 2.582

5.  Clinical validation of reduction in cocaine frequency level as an endpoint in clinical trials for cocaine use disorder.

Authors:  Corey R Roos; Charla Nich; Chung Jung Mun; Theresa A Babuscio; Justin Mendonca; André Q C Miguel; Elise E DeVito; Sarah W Yip; Katie Witkiewitz; Kathleen M Carroll; Brian D Kiluk
Journal:  Drug Alcohol Depend       Date:  2019-10-21       Impact factor: 4.492

6.  Contingency management for treatment attendance: A meta-analysis.

Authors:  Rory A Pfund; Meredith K Ginley; Carla J Rash; Kristyn Zajac
Journal:  J Subst Abuse Treat       Date:  2021-06-24

7.  Long-term functioning to provide empirical support for the clinical relevance of treatment outcomes for methamphetamine use disorders.

Authors:  André Q C Miguel; Crystal L Smith; Ekaterina Burduli; John M Roll; Sterling McPherson
Journal:  J Subst Abuse Treat       Date:  2021-01-14

8.  Detecting change in psychiatric functioning in clinical trials for cocaine use disorder: sensitivity of the Addiction Severity Index and Brief Symptom Inventory.

Authors:  Brian D Kiluk; Corey R Roos; Mihaela Aslan; Ralitza Gueorguieva; Charla Nich; Theresa A Babuscio; Kathleen M Carroll
Journal:  Drug Alcohol Depend       Date:  2021-09-20       Impact factor: 4.492

9.  Beyond abstinence and relapse II: momentary relationships between stress, craving, and lapse within clusters of patients with similar patterns of drug use.

Authors:  Leigh V Panlilio; Samuel W Stull; Jeremiah W Bertz; Albert J Burgess-Hull; Stephanie T Lanza; Brenda L Curtis; Karran A Phillips; David H Epstein; Kenzie L Preston
Journal:  Psychopharmacology (Berl)       Date:  2021-02-08       Impact factor: 4.415

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.